The Scientific and Organising Committees would like to invite you to be a part of the New Directions in Leukaemia Research (NDLR) Meeting 2026 being held in Adelaide, Australia from Monday 2 March to Wednesday 4 March 2026. 

The goal of the NDLR Meeting is to bring together scientists and clinicians to discuss emerging paradigms and breakthroughs at the forefront of blood cancer research. Blood cancers covered in-depth at the conference include multiple myeloma, myelofibrosis, lymphoma, childhood lymphoblastic leukaemia, chronic lymphocytic leukaemia and acute myeloid leukaemia. A key strength of NDLR is to present novel mechanisms of action and new therapeutic modalities that have just been or are about to be approved for patients with blood cancers.

As one of the premier international blood cancer meetings, NDLR 2026 will again bring together early career investigators, senior scientists, clinicians and key-opinion leaders for specific disease subtypes. Attendees will hear of recent findings in basic and translational research through interaction with local and international experts, forging new collaborations. Blood cancer research has undergone an unprecedented revolution in recent years and this is beginning to deliver a real and significant impact in the clinic, and Australia is a key contributor to many of these breakthroughs. The biennial NDLR Meeting offers a unique opportunity for scientists and clinicians to keep pace with such a rapidly evolving field and therefore offers sponsoring organisations unrivalled exposure and recognition.

This Meeting also provides the opportunity for the industry to interact with experts in the field of leukaemia research and clinical haematology (haematologists/oncologists). We look forward to having you participate as a sponsor or exhibitor at NDLR 2026. 

Dr Catherine Carmichael and Associate Professor Daniel Thomas 
NDLR 2026 Co-Chairs